US20120325669A1 - Nanohair structure and an application therefor - Google Patents
Nanohair structure and an application therefor Download PDFInfo
- Publication number
- US20120325669A1 US20120325669A1 US13/225,167 US201113225167A US2012325669A1 US 20120325669 A1 US20120325669 A1 US 20120325669A1 US 201113225167 A US201113225167 A US 201113225167A US 2012325669 A1 US2012325669 A1 US 2012325669A1
- Authority
- US
- United States
- Prior art keywords
- nanotemplate
- nanohair
- nanohair structure
- structure according
- nickel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002105 nanoparticle Substances 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 57
- 239000002070 nanowire Substances 0.000 claims abstract description 32
- 239000002086 nanomaterial Substances 0.000 claims abstract description 16
- 229910052759 nickel Inorganic materials 0.000 claims description 56
- 102000013394 Troponin I Human genes 0.000 claims description 29
- 108010065729 Troponin I Proteins 0.000 claims description 29
- 230000008569 process Effects 0.000 claims description 25
- 239000012528 membrane Substances 0.000 claims description 22
- 238000001020 plasma etching Methods 0.000 claims description 17
- 229910052751 metal Inorganic materials 0.000 claims description 14
- 239000002184 metal Substances 0.000 claims description 14
- 239000011148 porous material Substances 0.000 claims description 13
- 239000003550 marker Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 239000000956 alloy Substances 0.000 claims description 5
- 229910045601 alloy Inorganic materials 0.000 claims description 5
- 229920001940 conductive polymer Polymers 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 229910052737 gold Inorganic materials 0.000 claims description 5
- 229910021645 metal ion Inorganic materials 0.000 claims description 5
- 229910052763 palladium Inorganic materials 0.000 claims description 5
- 229910052709 silver Inorganic materials 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 238000004070 electrodeposition Methods 0.000 claims description 3
- 230000003100 immobilizing effect Effects 0.000 claims description 3
- 150000004767 nitrides Chemical class 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 229910052723 transition metal Inorganic materials 0.000 claims description 2
- 150000003624 transition metals Chemical class 0.000 claims description 2
- 230000010399 physical interaction Effects 0.000 abstract 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 110
- 238000003556 assay Methods 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 241000700721 Hepatitis B virus Species 0.000 description 22
- 239000002033 PVDF binder Substances 0.000 description 19
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 19
- 239000000872 buffer Substances 0.000 description 18
- 230000035945 sensitivity Effects 0.000 description 14
- 210000000234 capsid Anatomy 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 102000004903 Troponin Human genes 0.000 description 10
- 108090001027 Troponin Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 108090000565 Capsid Proteins Proteins 0.000 description 8
- 238000005498 polishing Methods 0.000 description 8
- 230000002194 synthesizing effect Effects 0.000 description 8
- 102100023321 Ceruloplasmin Human genes 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000012286 ELISA Assay Methods 0.000 description 6
- 238000005530 etching Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 5
- 239000011149 active material Substances 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 238000005054 agglomeration Methods 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000005424 photoluminescence Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000002096 quantum dot Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 3
- 238000003917 TEM image Methods 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 3
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229910015844 BCl3 Inorganic materials 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011258 core-shell material Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 101800000515 Non-structural protein 3 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000007845 assembly PCR Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 101150113754 cca gene Proteins 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000025339 heart septal defect Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000011943 nanocatalyst Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000006506 pH homeostasis Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- -1 poly sulfur nitride Chemical class 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920000767 polyaniline Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 229920000123 polythiophene Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000010420 shell particle Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D5/00—Electroplating characterised by the process; Pretreatment or after-treatment of workpieces
- C25D5/02—Electroplating of selected surface areas
- C25D5/022—Electroplating of selected surface areas using masking means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to a nanohair structure and a use thereof.
- a producing method can largely be classified into an infiltration method (after immersing a support into a solution dissolving an active material, the active material is supported at the support by evaporating or adding a precipitate), an ion exchange method (an active material is exchanged to a support by contacting the support with the solution dissolving the active material), a precipitation method (passing through a activating process by precipitating the active material in a solution state), and the like.
- the present invention which is a specific method out of the infiltration method of metal catalyst, uses a metal nickel as a catalyst.
- the nickel is easily made in desired shapes and desired sizes by using a nanotemplate as compared with a metal line, a metal thin film, a metal crystal, and the like by using the nickel are often used to study a catalytic action.
- the surface of the nickel nanohair structure can be biofunctionalized to achieve applicability in the field of biotechnology (BT).
- the exposed part of nickel nanowire is possible to use in a biosensor using an affinity of antibody-antigen and biotin-avidin through a surface modification.
- the applicability of nickel is greatly improved because the nickel can be possible to selectively bind with a variety of ligands such as amine and histidine.
- the nickel nanohair structure according to the present invention is a very useful nanomaterial for chemically detecting because it is uniform in height; the agglomeration phenomenon is prevented by being inside the nanotemplate; and it has a high density. Accordingly, a method for synthesizing a nanostructure for studying the nickel nanohair structure is required.
- An object of the present invention which is created by a necessity as mentioned above to solve the above problems, provides a nanohair structure which is necessary to prepare nanosensor.
- Another object of the present invention provides a three-dimensional nanostructure-based ultra-sensitive biosensor based on the nanohair structure.
- the present invention provides a nanohair structure comprising:
- nanotemplate comprising a plurality of pores; and (b) a plurality of nanowires grown through the pores of the nanotemplate, wherein one portion of the nanowires is embedded inside the nanotemplate, while the other portion of the nanowires is exposed vertically on top of the surface of the nanotemplate.
- nanohair structure which is used as its widest mean, in the present invention means the structure of exposing the nanowire array equalizing the length of nanowire by using semiconductor process such as the chemical mechanical planarization (CMP) process and the reactive ion etching (RIE) process, after filling metal (for example, nickel) in nanotemplate (for example, AAO nanotemplate).
- CMP chemical mechanical planarization
- RIE reactive ion etching
- the exposed nanowire is derived from electrically conductive material such as transition metal species and alloy thereof comprising Ni, Fe, Co, Ni, Cu, Ag, Au, Pd and Pt or electrically conductive polymer.
- electrically conductive material such as transition metal species and alloy thereof comprising Ni, Fe, Co, Ni, Cu, Ag, Au, Pd and Pt or electrically conductive polymer.
- the ‘electrically conductive polymer’ in the present invention means a light electrically conductive polymer with easy processing.
- the polymer is a long chain molecule compared with prior low molecular material and become solid state (crystal) by aggregation of the polymer chains.
- the electrically conductive polymer is preferably polyacetylene, polyaniline, polypyrrole, polythiophene, poly sulfur nitride etc, but is not limited thereto.
- the nanotemplate is preferably hard material like anodized aluminum oxide (AAO) or soft material like poly-carbonate, but is not limited thereto.
- AAO anodized aluminum oxide
- the present invention provides the method of the nanohair structure comprising, a) preparing a nanotemplate with a plurality of pores; b) generating a conductive electrode layer on one side of the nanotemplate; c) putting the nanotemplate into the solution containing the metal ion and growing the metal nanowire through pores of the nanotemplate by electrodeposition method employing it as a cathode; d) planarization of the metal nanowires through chemical mechanical planarization (CMP); and e) selective reactive ion etching (RIE) of the nanotemplate.
- CMP chemical mechanical planarization
- RIE selective reactive ion etching
- the thickness of deposition of step b) preferably is 250-350 nm, but is not limited thereto.
- the metal ion is preferably selected from the group consisting of Ni, Fe, Co, Ni, Cu, Ag, Au, Pd and Pt, but is not limited thereto.
- the solution containing the metal ion of step c) preferably is the mixture solution of metal sulfate, nickel chloride and boric acid, but is not limited thereto.
- the process of reactive ion etching of step e) preferably is to etch the nanotemplate for 10 min in an etching rate of 0.25 ⁇ m/min using BCl 3 gas, but is not limited thereto.
- precious metal such as Cu, Ag, Au, or Pt is mainly used in the electrode layer, but all kind of conductive thin film can be used in the electrode layer
- Pt is mainly used in the anode layer, but Pd or Ir can be used in the anode layer, but is not limited thereto.
- the present invention provides a three-dimensional nanostructure-based biosensor produced by adding chimeric nanoparticles on the surface of nanohair structure and immobilizing the chimeric nanoparticle to the structure.
- the chimeric nanoparticle is preferably HBV derived-chimeric protein, but is not limited thereto.
- the nanosensor preferably further comprises antibody which recognizes specific disease marker, but is not limited thereto.
- the disease marker is preferably Troponin I, but is not limited thereto.
- the producing method of the present invention preferably includes as follows: a) obtaining two gene clones that are derived from Hepatitis B virus core protein (HBVcAg) gene encoding synthesizes of N-NdeI-hexahistidine-HBVcAg(1-78)-G4SG4T-XhoI-C and N-BamH1-G4SG4-HBVcAg (81-149)-HindIII-C; b) producing other two clones, i.e., N-XhoI-SPA B -EcoRI-C and N-EcoRI-SPA B -BamHI-C in order to substituting P79A80 of HBVcAg with tandem repeat of 209-270 residues of B domain of Staphylococcal protein A (SPA B ); c) producing a plasmid expressing vector encoding the synthesis of N-His 6 -HBVcAg (1-78)-SPA B
- the ‘chimeric protein’ or ‘chimeric nanoparticle,’ which is used as its widest mean, in the present invention means the protein or protein nanoparticles with various functionalities by combining a foreign bio material to the surface of the protein nanoparticles based on a genetic engineering and a protein engineering technique.
- HBV capsid of the present invention is used as a model virus scaffold for a surface display of SPA B
- other viruses or virus-like particles can be used for the production of chimeric protein or chimeric nanoparticles displaying a surface SPA B .
- the ‘HBV-derived chimeric protein means the protein or protein nanoparticles with various functionailities by combining a foreign protein to the HBV-derived protein.
- the nanosensor in the present invention means device which detects specific compound, molecule or biomaterial like DNA or protein in the gas or liquid, or measures partial pressure or concentration of specific molecule or measures degree of vacuum of vacuum device or vacuum chamber or searching a site of gas leak.
- the present invention provides nanohair-based electrodes which offer increased surface area compared to the conventional flat surface electrodes, and thereby increase the electrochemical or biological reactions of materials (for example, ions or enzymes).
- FIG. 1 shows a process mimetic diagram of a fabrication method of nanohair wire structure:
- FIG. 1( a ) shows the synthesize of anodized aluminum oxide nanotemplate;
- FIG. 1( b ) shows the deposition of conductive layer (Ag, 300 ⁇ 400 nm) by E-beam evaporation;
- FIG. 1( c ) shows the synthesize of nanowires inside the nanotemplate;
- FIG. 1( d ) shows the planarization process of nanowires and nanotemplate;
- FIG. 1( e ) shows a selective etching process of nanotemplate for nanohair wire structure.
- FIG. 2 shows Field Emission-Scanning Electron Microscope (FE-SEM) images of nickel nanohair wire structure according to Example of the present invention:
- FIGS. 2( a ) and ( b ) show floor plans that are planarized by chemical mechanical planarization (CMP) process;
- FIGS. 2( c ) and ( d ) show cross-sectional diagrams that are planarized by the CMP process;
- FIGS. 2( e ) and ( f ) show cross-sectional diagrams of nickel nanohair wire structure by selective reactive ion etching (RIE) process of nanotemplate.
- CMP chemical mechanical planarization
- FIGS. 2( e ) and ( f ) show cross-sectional diagrams of nickel nanohair wire structure by selective reactive ion etching (RIE) process of nanotemplate.
- RIE reactive ion etching
- FIGS. 3 and 4 show three-dimensional diagnostic assay based on virus nanoparticles.
- FIG. 3 shows schematic and TEM images of native hepatitis B virus (HBV) capsid particles and chimeric nanoparticles synthesized in E. coli and
- FIG. 4 shows schematic, of the diagnostic system performed in a 96-well microplate and the assay principle in detail. Briefly, antibodies that recognize the disease marker (Troponin I in this case) bind to the chimeric nanoparticle and are oriented in a specific way. Troponin I binds to the antibodies and detection is achieved with secondary antibodies conjugated with quantum dots.
- HBV hepatitis B virus
- FIGS. 5 and 6 show the detection of Troponin I.
- FIG. 5 shows that the conventional ELISA assay could not detect Troponin I at concentrations lower than 0.1 nM
- FIG. 6 shows that the assay using chimeric nanoparticles and nickel nanohairs shows 10 ⁇ 18 (atto-molar, aM) sensitivities in both PBS and human sera.
- “Control” refers to the experiment in which only quantum-dot-secondary antibodies were added to the nickel nanohair surface, which was covered with a sufficient amount of chimeric nanoparticles (30 nM in PBS buffer 50
- FIGS. 7 and 8 show a washable and reuseable assay system.
- FIG. 7 shows Four-step protocol for washing and reusing the nickel nanohairs for detection.
- FIG. 8 shows the consecutive assays of eight different Troponin I (Tn) samples using three separate systems, showing good reproducibility.
- A, B, C, D, dotted and solid arrows, and PL1/PL2 correspond to those in FIG. 7 .
- Black areas of the rectangle represent net PL increase.
- FIGS. 9 and 10 show Troponin I assay on PVDF membranes.
- FIG. 9 shows that chimeric nanoparticles immobilized on PVDF membranes show similar detection sensitivities in both PBS and human sera.
- FIG. 10 shows that antibodies immobilized directly on the PVDF membranes show significantly lower sensitivities than those immobilized on chimeric nanoparticles.
- FIGS. 11 and 12 show clinical specificity and sensitivity of the viral chimeric nanoparticle-based assay.
- assays of sera derived from 16 healthy individuals and 26 AMI patients using the chimeric nanoparticles and PVDF membrane system [see FIG. 11( a )] unambiguously detected Troponin I in all patients, but using an ELISA-based diagnosis [see FIG. 11( b )] failed to detect three patients (Nos. 4, 9, and 18) and revealed nine ambiguous signals close to the clinical cutoff signal (horizontal dotted line).
- FIG. 12 shows assays with antibodies attached to chimeric nanoparticles, but not those immobilized directly on PVDF membranes, could detect Troponin I in a sample diluted 1,000 times. 74/M and 75/F represent the age and gender of the AMI patients.
- FIG. 13 shows a graph for determining an amount of HVB capsid-derived chimeric nanoparticles added to bare nickel surface, preventing the binding of non-specific quantum-dot-secondary antibodies to the nickel surface.
- Example 1 of the present invention relates to a method for forming Nanohair structure having an exposed nanowire structure on the anodized aluminum oxide (AAO) nanotemplate after synthesizing the nickel nanowires in the AAO nanotemplate.
- An object of the present invention is to provide a development of bio-nano catalyst material that can be possible to apply in vitro by using the nanowire as a catalyst for the application in the biochemical field.
- the technique according to Example 1 of the present invention is based on an electrochemistry, and relates to a producing method that would allow the mass production of a catalyst at low cost, in which the catalyst can increase the reaction rate, that is, can make the reaction of low activation energy by contacting with a reactant.
- the technique can be implemented by exposing the nickel nanowire through a selective isotropy reactive ion etching (RIE), after synthesizing the nickel nanowire in AAO nanotemplate produced by an electrodeposition method.
- RIE selective isotropy reactive ion etching
- a producing process of the nickel nanostructure according to the present invention includes regularly planarizing the heights of nanowire and AAO through a chemical mechanical planarization (CMP), after synthesizing the nanowire in the AAO nanotemplate by using an electrochemical method.
- AAO nanotemplate of the sample resulted from the above steps is selectively etched through an etching process by using a reactive ion etching (RIE) apparatus.
- RIE reactive ion etching
- the nanohair structure (Ni nanohair structure) exposed on the final AAO nanotemplate like hairs can be synthesized through the processes as mentioned above.
- the nanohair structure implemented as mentioned above does not have an agglomeration phenomenon of nanowires, and has very high density (10 8 wires/cm 2 ) and a regular height (max. 60 ⁇ m) so that its applicability is largely increased as a catalyst in the biochemical and environmental fields.
- the ‘chemical mechanical planarization (CMP)’ is one of the methods generally used in the process of planarizing, and includes pressing the action surface to the rotation polishing pad and then introducing a polishing and/or chemical reaction solution that is known as slurry on the polishing pad.
- the mechanical effect of pressure is applied through the polishing pad, and the chemical reaction caused by the input of slurry allows the materials to be selectively removed from the action surface thereby a little more equalizing the layer.
- deionized water having a high purity is applied to the polishing solution as base, and a particle and/or chemical additive having the effect of polishing is added therein.
- the more information about the chemical mechanical polishing, the slurry, and the like is disclosed in U.S. Pat. Nos. 6,914,001 and 6,887,137.
- Troponin I disclosed in the specification of the present invention is a type of proteins found in the blood of patients suffered from a cardiac infarction, and when detecting in the existence of Troponin I, it can be judged to have a disorder of heart.
- the ‘nickel nanohair structure’ disclosed in the specification of the present invention is the structure of exposing the nanowire by selectively etching AAO nanotemplate using the reactive ion etching (RIE) process, and equalizing the length of nanowire by using the chemical mechanical planarization (CMP) process, after synthesizing nickel nanowire in AAO nanotemplate.
- RIE reactive ion etching
- CMP chemical mechanical planarization
- PVDF membrane poly(vinyl difluoride) membrane
- the ‘PVDF membrane (poly(vinyl difluoride) membrane)’ disclosed in the specification of the present invention is the polymer membrane having small pores and hydrophobic property (no compatibility with water), and the present invention used the membrane having the pore of 450 nm size, in which the membrane has the property that allows the surface thereof to easily well take the nanoparticles.
- bio-nano-probe disclosed in the specification of the present invention is used as the material of sensor that is accumulated with the probe for detecting a target to the protein nanoparticles.
- the present inventors showed that combining the three-dimensional nanostructure including the nickel nanohair and virus nanoparticles that are designed to have a dual affinity for antibodies and nickel can detect at low level of Troponin, i.e., 10 6 ⁇ 10 7 in human serum as compared with using the typical ELISA assay [Hirsch, L. R., Jackson, J. B., Lee, A., Halas, N. J. & West, J. Anal. Chem. 75, 2377-2381 (2003); Nam, J. M., Park, S. J. &Mirkin, C. A. J. Am. Chem. Soc. 124, 3820-3821 (2002); Niemeyer, C. M. & Ceyhan, B. Angew.
- the virus nanoparticles help the orientation of antibodies for the maximum capture of Troponin marker.
- Troponin marker is largely bound to antibody in the high density combined to the nanostructure, the sensitivity of detecting is largely increased.
- the nickel nanohair is able to reproduce and also to regeneratively distinguish a healthy serum from unhealthy serum.
- the present inventors anticipate other virus nanoparticles forming a diagnosis assay with high similar sensitivity to other various protein markers.
- HBV core protein consisting of four long alpha-helix bundles ( FIG. 3 ), when expressed in bacteria, assembles into core-shell particles that closely resemble the native capsid structure of virus [Bottcher, B., Wynne, S. A. & Crowther, R. A. Nature 386, 88-91 (1997); Crowther, R. A. et al. Cell 77, 943-950 (1994)].
- Bottcher and colleagues demonstrated that a single HBV core protein truncated after residue 149 forms the core-shell particles that contain 240 subunits and have an overall diameter of 36 nm [Bottcher, B., Wynne, S. A.
- the dimer clustering of the subunits produces spikes on the surface of the shell particle, and the immunogenic epitope is located at the tips of prominent surface spikes ( FIG. 3 ).
- the surface-exposed spike tip corresponds to the loop segment consisting of the residues from D78 to D83 of the single core protein.
- the present inventors made that the P79A80 in the loop segment was replaced with the tandem repeated SPA B sequences (NCBI nucleotide accession No. M18264 nucleotide sequence 625-813, Sequence No. 11), which were subsequently exposed on the surface of the synthesized chimeric nanoparticles with high density ( FIG. 3 ).
- the present inventors also added the hexahistidine sequence to the N-terminus of the truncated HBV core protein so that the chimeric nanoparticles would have a strong affinity for nickel ( FIG. 3 ).
- Transmission electron microscopy (TEM) image analysis FIG. 3 ) revealed that the HBV capsid-derived chimeric nanoparticles that were expressed in E. coli assembled into spherical nanoparticles with a nearly native diameter. Consequently, the chimeric nanoparticles have a dual affinity for the Fc domain of antibodies (IgG) and nickel.
- IgG antibodies
- These viral particles can display on their surface various peptides and proteins that are used for detecting and/or quantifying bimolecular of interest.
- nanohair refers to an array of nanowires in which some wires are exposed to the air, the rest being embedded in the body of a supporting organic or inorganic template ( FIG. 4 ). In these structures, the air-exposed portion of the nanowires has a greatly increased surface-to-volume ratio.
- the efficient three-dimensional assay system was developed with the following significant advantages: (i) maximum accessibility of protein markers to antibodies, enabled both by the controlled orientation of the antibodies and the three-dimensional manner of protein capture, and (ii) a dramatically increased density and ratio of antibodies to protein markers on the three-dimensional nanohair surface.
- the captured markers were detected by sensing photoluminescence emitted by quantum dots conjugated to the secondary antibodies ( FIG. 4 ).
- one nickel nanohair structure can be repeatedly used for multiple samples. Through washing and rinsing (i.e., in the step A of FIG. 7 ), the used nickel nanohair was refreshed and reused for another sample assay. All of the three separate nickel nanohair structures were successfully used for the consecutive assay of eight different samples. Each consecutive assay showed reproducible and consistent signals for all the samples tested.
- PVDF polyvinylidene fluoride
- the present inventors also tested the PVDF-based assay system in the clinical diagnosis of 26 AMI patients (Table 1) who were confirmed to have experienced an AMI, and the assay results were compared with the ELISA-based assay (a and b of FIG. 11 ).
- Table 1 the clinical diagnosis of 26 AMI patients
- the assay results were compared with the ELISA-based assay (a and b of FIG. 11 ).
- three (Nos. 4, 9, and 18) AMI patient sera were not positively detected; that is, the absorbance signals were below the clinical cutoff value (indicated by the horizontal dotted line), and the signals from nine (Nos. 1, 2, 3, 5, 8, 11, 16, 17, and 23) AMI patient sera were positive but very close to the clinical cutoff.
- the chimeric nanoparticles and PVDF-based assay gave clear positive signals for all 26 AMI patient sera, therefore indicating 100% clinical specificity ( FIG. 11 ).
- the ELISA assay results were not surprising because the clinical specificity of the ELISA kit is reported by the supplier to be 87.5%.
- antibodies directly immobilized on the PVDF surface failed to diagnose the 1,000-times diluted AMI patient sera, whereas the chimeric nanoparticles and PVDF-based assay could detect Troponin I in the diluted patient sera ( FIG. 12 ), indicating that this three-dimensional assay can discriminate the onset of AMI even with an extremely small quantity of patient sera.
- HBV capsid-derived chimeric nanoparticles and three-dimensional nanostructures we were able to develop a highly sensitive and specific assay system for the specific AMI marker, Troponin I.
- HBV capsid according to the present invention was used in this study as a model viral scaffold for the surface display of SPA B , other viruses or virus-like particles could also be used for the production of chimeric nanoparticles, displaying the surface SPA B . Owing to the controlled orientation of densely immobilized antibodies and the three-dimensional manner of protein capture, the assay sensitivity and clinical specificity were significantly enhanced as compared to the conventional ELISA assay.
- the nanohair wire structure according to the present invention which is a method for chemically detecting that has a yield of a high efficiency due to the exclusion of agglomeration phenomenon among the nanowires, has a high applicability in the flied of Biotechnology (BT) as well as Nanotechnology (NT) by synthesizing the nanowire material having a biological functionality inside the nanotemplate.
- BT Biotechnology
- NT Nanotechnology
- the present invention showed that the assay system according to the present invention using chimeric nanoparticles and three-dimensional nanostructure (nickel nanohair and PVDF membrane) has a very higher sensitivity and specificity as the use of detecting the disease diagnosis marker and has very high sensitivity and specificity to the protein marker, such as Troponin I or specific AMI marker.
- the anodized aluminum oxide (AAO) nanotemplate with uniform pore diameter (tens to hundreds nm) as shown in FIG. 1( a ) was synthesized. And then, Ag as a working electrode was deposited one side of AAO in a thickness of 250-350 nm using E-beam evaporator as shown in FIG. 1( b ). Then, after adding AAO to the solution of nickel sulfate (NiSO 4 6H 2 O, 0.5 M)+nickel chloride (NiCl 2 .6H 2 O, 0.1M)+boric acid (H 3 BO 3 , 0.1M) as shown in FIG. 1( c ), Pt as a counter electrode was deposited to the nickel nanowires.
- nickel sulfate is a main component of plating; nickel chloride was used for increasing an electrical conductivity; and boric acid was used as a buffer solution for pH homeostasis.
- polishing was performed about 10 ⁇ m through a chemical mechanical planarization (CMP) process for identifying AAO nanotemplate with the height of nanowires that were overflow or underflow-gtown inside the AAO.
- CMP chemical mechanical planarization
- a selective reactive ion etching (RIE) process of AAO nanotemplate was performed in order to expose the nickel nanowires.
- the process was performed by etching AAO for 10 min at an etching rate of 0.25 ⁇ m/min using BCl 3 (100%) gas.
- a cleaning process DI water: ultrapure water, ethanol was completed, finishing the process of the nickel nanohairs structure with a clean surface.
- HBV core protein HBV core protein
- N-XhoI-SPA a -EcoRI-C and N-EcoRI-SPA a -BamHI-C were prepared.
- plasmid expression vector pT7-Chimera-HBV encoding the synthesis of N-His 6 -HBVcAg(1-78)-SPA B -SPA B -HBVcAg(81-149)-C.
- Table 1 shows primer sequences, in which bold types represent restriction enzymes sequences; underlined parts represent linker sequences; and italic types represent 6 histidine sequences.
- HBV capsid-derived chimeric nanoparticles can be largely divided into 1-78 amino acid sequence regions of capsid protein, the region including continuously two Staphylococcal protein A, and 81-149 amino acid sequences regions of capsid protein (1-78 sequences of capsid protein is NCBI Nucleotide accession number: AF286594 sequences: 1901-2134 (Sequence No. 12) and amino acid sequence (Sequence No. 13); 81-149 sequences of capsid protein is 2141-2347 sequences (Sequence No. 14) of AF286594; and the amino acid sequence is Sequence No. 15, and Protein A sequence is NCBI nucleotide accession No. M18264, nucleotide sequence 625-813 (Sequence No. 11); and the amino acid is Sequence No. 16).
- the first region was subjected to extension PCR using the primer sequence region 1 including 6 histidines using the gene sequence of HBV capsid protein (1901-2452 sequences of NCBI Nucleotide accession number: AF286594 sequences) as a template, and the primer sequences 2 and 3 including a linker sequence (amino sequences GGGGSGGGGT).
- PCR was performed by using the primer sequences 1 and 3 using the synthesized PCR products as the templates.
- PCR product consisting of 5′-NdeI-HBV capsid protein (1-78 amino acid sequences)-linker sequence (GGGGSGGGT)-XhoI-3′ was obtained.
- the third region was subjected to extension PCR using the primer sequence 6, and the primer sequences 4 and 5 including the linker sequence (Amino acid sequence GGGGSGGGG) through using HBV capsid protein gene sequence as a template.
- PCR was performed by using the primer sequences 4 and 6 through using the synthesized PCR products as a template.
- PCR product consisting of 5′-BamHI-linker sequence (GGGGSGGGG)-HBV capsid protein (81-149 amino acid sequence)-HindIII-3′ was obtained.
- the nickel nanohair structure prepared by the above Example 1 was placed in the Costar 96-well plate (Cat. No. 3599, Corning, N.Y., USA). Before immobilizing the chimeric nanoparticles, the nickel nanohair in each well was washed four times for 15 min using 0.3 M sulphuric acid and then six times for 10 min using distilled water, then completely dried. Next, the background photoluminescence from the nickel nanohair structure was measured using a microplate reader (GENios, Tecan, Austria) with excitation and emission at 420 and 650 nm, respectively.
- PBS buffer 50 ⁇ l containing the 38-nM chimeric nanoparticles prepared from Example 2 was added to the nickel nanohair structure, followed by slow agitation for 30 min, after which it was washed with 50 mM Tris buffer (pH 7.4).
- Rabbit anti-troponin polyclonal antibody (5 ⁇ g/ml, Cat. No. ab470003, Abcam, Cambridge, UK) in 200 ⁇ l PBS buffer was added to the chimeric nanoparticles that were already immobilized on the nickel nanohair, by slowly stirring the nickel nanohair in the antibody-containing PBS buffer for 2 h.
- PVDF membrane (Immobilion-FL, IPFL 10100, Millipore, Mass., U.S.A.) in a Costar 96-well plate was pre-wetted with methanol for 1 min and washed with a PBS buffer (137 mM, NaCl; 2.7 mM, KCl; 10 mM, Na 2 HPO 4 ; 2 mM, KH 2 PO 4 ; pH, 7.4) for 5-10 min. Before the PVDF membrane was completely dried, 10 a of PBS buffer containing the chimeric nanoparticles purified in Example 2 was dropped onto a designated spot on the membrane.
- PBS buffer 137 mM, NaCl; 2.7 mM, KCl; 10 mM, Na 2 HPO 4 ; 2 mM, KH 2 PO 4 ; pH, 7.4
- the membrane was then slowly stirred for 1 h in the blocking solution (1% skimmed milk) and washed twice with the PBS buffer for 30 min.
- Goat anti-Troponin I polyclonal antibodies (20 ⁇ g/ml in PBS buffer; Cat. No. 70-XG82, Fitzgerald, Mass., USA) was added to the chimeric protein nanoparticles that were already immobilized onto the PVDF membrane, by slowly stirring the membrane in the antibody-containing 200 ⁇ l PBS buffer for 2 h.
- ELISA assay experiments in the present invention were conducted using the commercial ELISA Troponin assay kit (Troponin I EIA, Cat. No 25-TR1HU-E01, 96 wells, ALPCO Diagnostics, NH, USA) that was developed for in vitro diagnostic use. In short, it is as follows: 1) 100 ⁇ l of human serum (AMI patient or healthy serum) or Troponin (human cardiac Troponin I-T-C complex, Cat. No.
- Troponin I EIA provides a reliable assay for the quantitative measurement of human cardiac-specific Troponin I with a clinical specificity of 87.5
- the procedure disclosed in Troponin I EIA protocol was strictly followed for the Troponin I assay, and the assay procedure is as follows. The entire list of AMI patients and healthy sera are disclosed in Table 2.
Abstract
There is provided a nanohair structure with the nanowires exposed on a nanotemplate; the method thereof; and a three-dimensional nanostructure-based sensor with ultra-sensitivity and greatly increased three-dimensional surface-to-volume ratio which immobilizes bio-nanoparticles to the nanohair structure and arranges antibodies to the nano surface with the controlled orientation by physical interaction.
Description
- This application is a continuation of PCT/KR2010/001389 filed Mar. 5, 2010, which claims the benefit of Korean Application No. 10-2009-0019355 filed Mar. 6, 2009, the entire contents of which applications are incorporated herein by reference.
- The present invention relates to a nanohair structure and a use thereof.
- In general, there are many kinds of catalysts, such as a metal, an alloy, a metal oxide, and the like. In addition, a producing method can largely be classified into an infiltration method (after immersing a support into a solution dissolving an active material, the active material is supported at the support by evaporating or adding a precipitate), an ion exchange method (an active material is exchanged to a support by contacting the support with the solution dissolving the active material), a precipitation method (passing through a activating process by precipitating the active material in a solution state), and the like. Of these, the present invention, which is a specific method out of the infiltration method of metal catalyst, uses a metal nickel as a catalyst. In addition, since the nickel is easily made in desired shapes and desired sizes by using a nanotemplate as compared with a metal line, a metal thin film, a metal crystal, and the like by using the nickel are often used to study a catalytic action. For example, the surface of the nickel nanohair structure can be biofunctionalized to achieve applicability in the field of biotechnology (BT). Especially, the exposed part of nickel nanowire is possible to use in a biosensor using an affinity of antibody-antigen and biotin-avidin through a surface modification. Especially, the applicability of nickel is greatly improved because the nickel can be possible to selectively bind with a variety of ligands such as amine and histidine. In addition, it can also be possible to control the movement of nanostructure by using a magnetic property of nickel. However, it is extremely difficult to get the result of an individual nanowire property because an agglomeration phenomenon is generated due to a magnetic interaction and van der Waals forces for using the nickel nanowire that is completely separated from a nanotemplate with a plurality of nanopores such as an anodized aluminum oxide (AAO) membrane.
- Here, the nickel nanohair structure according to the present invention is a very useful nanomaterial for chemically detecting because it is uniform in height; the agglomeration phenomenon is prevented by being inside the nanotemplate; and it has a high density. Accordingly, a method for synthesizing a nanostructure for studying the nickel nanohair structure is required.
- Meanwhile, an early detection [Adams, J. E. et al. Circulation 88, 101-106 (1993); Adams, J. E., Schechtman, K. B., Landt, Y., Ladenson, J. H. & Jaffe, A. S. Clin. Chem. 40, 1291-1295 (1994); Thygesen, K., Alpert, J. S. & White, H. D. J. Am. Coll. Cardiol. 50, 2173-2195 (2007); Morrow, D. A. et al. Clin. Chem. 53, 552-574 (2007); Gibler, W. B. et al. Ann. Emerg. Med. 46, 185-197 (2005)] of Troponin I (Protein Marker) from a patient suffered with high risk acute myocardial infarction can reduce a risk rate of deaths from heart attack [Antman, E. M. et al. N. Engl. J. Med. 335, 1342-1349 (1996); Wu, A. H. B. & Jaffe, A. S. Am. Heart J. 155, 208-214 (2008); Benamer, H. et al. Am. Heart J. 137, 815-820 (1999); Heeschen, C., van den Brand, M. J., Hamm, C. W. & Simoons, M. L.
Circulation 100, 1509-1514 (1999); Wong, G. C. et al. Circulation 106, 202-207 (2002)]. - Most Troponin assays are currently based on the conventional Enzyme Linked Immunosorbent Assay (ELISA) and have detection limits in the nanomolar- and picomolar ranges [Rosi, N. L. & Mirkin, C. A. Chem. Rev. 105, 1547-1562 (2005)].
- The above information disclosed in this Background section is only for enhancement of understanding of the background of the invention and therefore it may contain information that does not form the prior art that is already known in this country to a person of ordinary skill in the art.
- An object of the present invention, which is created by a necessity as mentioned above to solve the above problems, provides a nanohair structure which is necessary to prepare nanosensor.
- Another object of the present invention provides a three-dimensional nanostructure-based ultra-sensitive biosensor based on the nanohair structure.
- In order to achieve the above objects, the present invention provides a nanohair structure comprising:
- (a) nanotemplate comprising a plurality of pores; and
(b) a plurality of nanowires grown through the pores of the nanotemplate, wherein one portion of the nanowires is embedded inside the nanotemplate, while the other portion of the nanowires is exposed vertically on top of the surface of the nanotemplate. - The ‘nanohair structure’ which is used as its widest mean, in the present invention means the structure of exposing the nanowire array equalizing the length of nanowire by using semiconductor process such as the chemical mechanical planarization (CMP) process and the reactive ion etching (RIE) process, after filling metal (for example, nickel) in nanotemplate (for example, AAO nanotemplate).
- For an embodiment of the present invention, the exposed nanowire is derived from electrically conductive material such as transition metal species and alloy thereof comprising Ni, Fe, Co, Ni, Cu, Ag, Au, Pd and Pt or electrically conductive polymer. After preparing nanohair by using the metal or alloy thereof, the exposed part of the nanohair can be modified into oxide, nitride and carbide through oxidation, nitrification or carburization of the exposed part.
- The ‘electrically conductive polymer’ in the present invention means a light electrically conductive polymer with easy processing. The polymer is a long chain molecule compared with prior low molecular material and become solid state (crystal) by aggregation of the polymer chains. For an embodiment of the present invention, the electrically conductive polymer is preferably polyacetylene, polyaniline, polypyrrole, polythiophene, poly sulfur nitride etc, but is not limited thereto.
- For an embodiment of the present invention, the nanotemplate is preferably hard material like anodized aluminum oxide (AAO) or soft material like poly-carbonate, but is not limited thereto.
- In addition, the present invention provides the method of the nanohair structure comprising, a) preparing a nanotemplate with a plurality of pores; b) generating a conductive electrode layer on one side of the nanotemplate; c) putting the nanotemplate into the solution containing the metal ion and growing the metal nanowire through pores of the nanotemplate by electrodeposition method employing it as a cathode; d) planarization of the metal nanowires through chemical mechanical planarization (CMP); and e) selective reactive ion etching (RIE) of the nanotemplate.
- For the method for producing the nanohair structure, the thickness of deposition of step b) preferably is 250-350 nm, but is not limited thereto.
- For the method for producing the nanohair structure, the metal ion is preferably selected from the group consisting of Ni, Fe, Co, Ni, Cu, Ag, Au, Pd and Pt, but is not limited thereto.
- For the method for producing the nanohair structure, the solution containing the metal ion of step c) preferably is the mixture solution of metal sulfate, nickel chloride and boric acid, but is not limited thereto.
- For the method for producing the nanohair structure, the process of reactive ion etching of step e) preferably is to etch the nanotemplate for 10 min in an etching rate of 0.25 μm/min using BCl3 gas, but is not limited thereto.
- For the method for producing the nanohair structure, precious metal such as Cu, Ag, Au, or Pt is mainly used in the electrode layer, but all kind of conductive thin film can be used in the electrode layer
- For the method for producing the nanohair structure, Pt is mainly used in the anode layer, but Pd or Ir can be used in the anode layer, but is not limited thereto.
- In addition, the present invention provides a three-dimensional nanostructure-based biosensor produced by adding chimeric nanoparticles on the surface of nanohair structure and immobilizing the chimeric nanoparticle to the structure.
- For an embodiment of the present invention, the chimeric nanoparticle is preferably HBV derived-chimeric protein, but is not limited thereto.
- For other embodiment of the present invention, the nanosensor preferably further comprises antibody which recognizes specific disease marker, but is not limited thereto.
- For other embodiment of the present invention, the disease marker is preferably Troponin I, but is not limited thereto.
- For an embodiment of the present invention, the producing method of the present invention preferably includes as follows: a) obtaining two gene clones that are derived from Hepatitis B virus core protein (HBVcAg) gene encoding synthesizes of N-NdeI-hexahistidine-HBVcAg(1-78)-G4SG4T-XhoI-C and N-BamH1-G4SG4-HBVcAg (81-149)-HindIII-C; b) producing other two clones, i.e., N-XhoI-SPAB-EcoRI-C and N-EcoRI-SPAB-BamHI-C in order to substituting P79A80 of HBVcAg with tandem repeat of 209-270 residues of B domain of Staphylococcal protein A (SPAB); c) producing a plasmid expressing vector encoding the synthesis of N-His6-HBVcAg (1-78)-SPAB-SPAB-HBVcAg (81-149)-C through a sequential ligation of the above four clones; and d) expressing the gene of chimeric protein by transforming the expression vector to a host, but it is not limited thereto.
- The ‘chimeric protein’ or ‘chimeric nanoparticle,’ which is used as its widest mean, in the present invention means the protein or protein nanoparticles with various functionalities by combining a foreign bio material to the surface of the protein nanoparticles based on a genetic engineering and a protein engineering technique. Although HBV capsid of the present invention is used as a model virus scaffold for a surface display of SPAB, other viruses or virus-like particles can be used for the production of chimeric protein or chimeric nanoparticles displaying a surface SPAB.
- For the present invention, the ‘HBV-derived chimeric protein, means the protein or protein nanoparticles with various functionailities by combining a foreign protein to the HBV-derived protein.
- The nanosensor in the present invention means device which detects specific compound, molecule or biomaterial like DNA or protein in the gas or liquid, or measures partial pressure or concentration of specific molecule or measures degree of vacuum of vacuum device or vacuum chamber or searching a site of gas leak.
- In addition, the present invention provides nanohair-based electrodes which offer increased surface area compared to the conventional flat surface electrodes, and thereby increase the electrochemical or biological reactions of materials (for example, ions or enzymes).
- The above and other features and advantages of the present invention will be apparent from or are set forth in more detail in the accompanying drawings, which are incorporated in and form a part of this specification, and the following Detailed Description, which together serve to explain by way of example the principles of the present invention.
- The above and other aspects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:
-
FIG. 1 shows a process mimetic diagram of a fabrication method of nanohair wire structure:FIG. 1( a) shows the synthesize of anodized aluminum oxide nanotemplate;FIG. 1( b) shows the deposition of conductive layer (Ag, 300˜400 nm) by E-beam evaporation;FIG. 1( c) shows the synthesize of nanowires inside the nanotemplate;FIG. 1( d) shows the planarization process of nanowires and nanotemplate; andFIG. 1( e) shows a selective etching process of nanotemplate for nanohair wire structure. -
FIG. 2 shows Field Emission-Scanning Electron Microscope (FE-SEM) images of nickel nanohair wire structure according to Example of the present invention: -
FIGS. 2( a) and (b) show floor plans that are planarized by chemical mechanical planarization (CMP) process;FIGS. 2( c) and (d) show cross-sectional diagrams that are planarized by the CMP process; andFIGS. 2( e) and (f) show cross-sectional diagrams of nickel nanohair wire structure by selective reactive ion etching (RIE) process of nanotemplate. -
FIGS. 3 and 4 show three-dimensional diagnostic assay based on virus nanoparticles.FIG. 3 shows schematic and TEM images of native hepatitis B virus (HBV) capsid particles and chimeric nanoparticles synthesized in E. coli andFIG. 4 shows schematic, of the diagnostic system performed in a 96-well microplate and the assay principle in detail. Briefly, antibodies that recognize the disease marker (Troponin I in this case) bind to the chimeric nanoparticle and are oriented in a specific way. Troponin I binds to the antibodies and detection is achieved with secondary antibodies conjugated with quantum dots. -
FIGS. 5 and 6 show the detection of Troponin I.FIG. 5 shows that the conventional ELISA assay could not detect Troponin I at concentrations lower than 0.1 nM, andFIG. 6 shows that the assay using chimeric nanoparticles and nickel nanohairs shows 10−18 (atto-molar, aM) sensitivities in both PBS and human sera. “Control” refers to the experiment in which only quantum-dot-secondary antibodies were added to the nickel nanohair surface, which was covered with a sufficient amount of chimeric nanoparticles (30 nM in PBS buffer 50 -
FIGS. 7 and 8 show a washable and reuseable assay system. -
FIG. 7 shows Four-step protocol for washing and reusing the nickel nanohairs for detection.FIG. 8 shows the consecutive assays of eight different Troponin I (Tn) samples using three separate systems, showing good reproducibility. A, B, C, D, dotted and solid arrows, and PL1/PL2 correspond to those inFIG. 7 . Black areas of the rectangle represent net PL increase. -
FIGS. 9 and 10 show Troponin I assay on PVDF membranes.FIG. 9 shows that chimeric nanoparticles immobilized on PVDF membranes show similar detection sensitivities in both PBS and human sera.FIG. 10 shows that antibodies immobilized directly on the PVDF membranes show significantly lower sensitivities than those immobilized on chimeric nanoparticles. -
FIGS. 11 and 12 show clinical specificity and sensitivity of the viral chimeric nanoparticle-based assay. In assays of sera derived from 16 healthy individuals and 26 AMI patients, using the chimeric nanoparticles and PVDF membrane system [seeFIG. 11( a)] unambiguously detected Troponin I in all patients, but using an ELISA-based diagnosis [seeFIG. 11( b)] failed to detect three patients (Nos. 4, 9, and 18) and revealed nine ambiguous signals close to the clinical cutoff signal (horizontal dotted line).FIG. 12 shows assays with antibodies attached to chimeric nanoparticles, but not those immobilized directly on PVDF membranes, could detect Troponin I in a sample diluted 1,000 times. 74/M and 75/F represent the age and gender of the AMI patients. -
FIG. 13 shows a graph for determining an amount of HVB capsid-derived chimeric nanoparticles added to bare nickel surface, preventing the binding of non-specific quantum-dot-secondary antibodies to the nickel surface. - Hereinafter, the present invention will be described with embodiments of the present invention. Embodiments of the method for synthesizing a metallic nanohair structure will be described with Examples of the present invention.
- The entire process of Example 1 is as depicted in FIG. 1. Example 1 of the present invention relates to a method for forming Nanohair structure having an exposed nanowire structure on the anodized aluminum oxide (AAO) nanotemplate after synthesizing the nickel nanowires in the AAO nanotemplate. An object of the present invention is to provide a development of bio-nano catalyst material that can be possible to apply in vitro by using the nanowire as a catalyst for the application in the biochemical field.
- The technique according to Example 1 of the present invention is based on an electrochemistry, and relates to a producing method that would allow the mass production of a catalyst at low cost, in which the catalyst can increase the reaction rate, that is, can make the reaction of low activation energy by contacting with a reactant. The technique can be implemented by exposing the nickel nanowire through a selective isotropy reactive ion etching (RIE), after synthesizing the nickel nanowire in AAO nanotemplate produced by an electrodeposition method.
- A producing process of the nickel nanostructure according to the present invention includes regularly planarizing the heights of nanowire and AAO through a chemical mechanical planarization (CMP), after synthesizing the nanowire in the AAO nanotemplate by using an electrochemical method. AAO nanotemplate of the sample resulted from the above steps is selectively etched through an etching process by using a reactive ion etching (RIE) apparatus. The nanohair structure (Ni nanohair structure) exposed on the final AAO nanotemplate like hairs can be synthesized through the processes as mentioned above. The nanohair structure implemented as mentioned above does not have an agglomeration phenomenon of nanowires, and has very high density (108 wires/cm2) and a regular height (max. 60 μm) so that its applicability is largely increased as a catalyst in the biochemical and environmental fields.
- The ‘chemical mechanical planarization (CMP)’ is one of the methods generally used in the process of planarizing, and includes pressing the action surface to the rotation polishing pad and then introducing a polishing and/or chemical reaction solution that is known as slurry on the polishing pad. The mechanical effect of pressure is applied through the polishing pad, and the chemical reaction caused by the input of slurry allows the materials to be selectively removed from the action surface thereby a little more equalizing the layer. Typically, deionized water having a high purity is applied to the polishing solution as base, and a particle and/or chemical additive having the effect of polishing is added therein. The more information about the chemical mechanical polishing, the slurry, and the like is disclosed in U.S. Pat. Nos. 6,914,001 and 6,887,137.
- The ‘Troponin I’ disclosed in the specification of the present invention is a type of proteins found in the blood of patients suffered from a cardiac infarction, and when detecting in the existence of Troponin I, it can be judged to have a disorder of heart.
- The ‘nickel nanohair structure’ disclosed in the specification of the present invention is the structure of exposing the nanowire by selectively etching AAO nanotemplate using the reactive ion etching (RIE) process, and equalizing the length of nanowire by using the chemical mechanical planarization (CMP) process, after synthesizing nickel nanowire in AAO nanotemplate.
- The ‘PVDF membrane (poly(vinyl difluoride) membrane)’ disclosed in the specification of the present invention is the polymer membrane having small pores and hydrophobic property (no compatibility with water), and the present invention used the membrane having the pore of 450 nm size, in which the membrane has the property that allows the surface thereof to easily well take the nanoparticles.
- The ‘bio-nano-probe’ disclosed in the specification of the present invention is used as the material of sensor that is accumulated with the probe for detecting a target to the protein nanoparticles.
- The present inventors showed that combining the three-dimensional nanostructure including the nickel nanohair and virus nanoparticles that are designed to have a dual affinity for antibodies and nickel can detect at low level of Troponin, i.e., 106˜107 in human serum as compared with using the typical ELISA assay [Hirsch, L. R., Jackson, J. B., Lee, A., Halas, N. J. & West, J. Anal. Chem. 75, 2377-2381 (2003); Nam, J. M., Park, S. J. &Mirkin, C. A. J. Am. Chem. Soc. 124, 3820-3821 (2002); Niemeyer, C. M. & Ceyhan, B. Angew. Chem., Int. Ed. 40, 3685-3688 (2001); Chien, R. J. et al. Proc. Natl. Acad. Sci. 100, 4984-4989 (2003) Wang, J., Polsky, R., Merkoci, A. & Turner, K. L. Angew. Chem., Int. Ed. 43, 2158-2161 (2004)] in the present invention. The virus nanoparticles help the orientation of antibodies for the maximum capture of Troponin marker. When Troponin marker is largely bound to antibody in the high density combined to the nanostructure, the sensitivity of detecting is largely increased. The nickel nanohair is able to reproduce and also to regeneratively distinguish a healthy serum from unhealthy serum. The present inventors anticipate other virus nanoparticles forming a diagnosis assay with high similar sensitivity to other various protein markers.
- Meanwhile, the HBV core protein, consisting of four long alpha-helix bundles (
FIG. 3 ), when expressed in bacteria, assembles into core-shell particles that closely resemble the native capsid structure of virus [Bottcher, B., Wynne, S. A. & Crowther, R. A. Nature 386, 88-91 (1997); Crowther, R. A. et al. Cell 77, 943-950 (1994)]. Through the electron cryomicroscopy analysis, Bottcher and colleagues demonstrated that a single HBV core protein truncated after residue 149 forms the core-shell particles that contain 240 subunits and have an overall diameter of 36 nm [Bottcher, B., Wynne, S. A. & Crowther, R. A. Nature 386, 88-91 (1997)]. The dimer clustering of the subunits produces spikes on the surface of the shell particle, and the immunogenic epitope is located at the tips of prominent surface spikes (FIG. 3 ). The surface-exposed spike tip corresponds to the loop segment consisting of the residues from D78 to D83 of the single core protein. The present inventors made that the P79A80 in the loop segment was replaced with the tandem repeated SPAB sequences (NCBI nucleotide accession No. M18264 nucleotide sequence 625-813, Sequence No. 11), which were subsequently exposed on the surface of the synthesized chimeric nanoparticles with high density (FIG. 3 ). In the chimeric nanoparticle synthesis, the present inventors also added the hexahistidine sequence to the N-terminus of the truncated HBV core protein so that the chimeric nanoparticles would have a strong affinity for nickel (FIG. 3 ). Transmission electron microscopy (TEM) image analysis (FIG. 3 ) revealed that the HBV capsid-derived chimeric nanoparticles that were expressed in E. coli assembled into spherical nanoparticles with a nearly native diameter. Consequently, the chimeric nanoparticles have a dual affinity for the Fc domain of antibodies (IgG) and nickel. These viral particles can display on their surface various peptides and proteins that are used for detecting and/or quantifying bimolecular of interest. - As illustrated in
FIG. 4 , a three-dimensional assay system was developed by combining the chimeric nanoparticles with a nickel nanohair structure or porous membrane, and then adding antibodies to specifically capture protein markers. For the present invention, the term ‘nanohair’ refers to an array of nanowires in which some wires are exposed to the air, the rest being embedded in the body of a supporting organic or inorganic template (FIG. 4 ). In these structures, the air-exposed portion of the nanowires has a greatly increased surface-to-volume ratio. - When antibodies are added to the chimeric nanoparticles that are already attached to the nickel nanohair surface as a result of the affinity interaction between the hexahistidin and nickel (
FIG. 3 ), the Fc domain of antibody (IgG) is specifically bound to the surface SPAS of the chimeric nanoparticles, and hence the antigen-specific variable domains of IgG are fully accessible to protein markers. Consequently, as illustrated inFIG. 4 , the efficient three-dimensional assay system was developed with the following significant advantages: (i) maximum accessibility of protein markers to antibodies, enabled both by the controlled orientation of the antibodies and the three-dimensional manner of protein capture, and (ii) a dramatically increased density and ratio of antibodies to protein markers on the three-dimensional nanohair surface. The captured markers were detected by sensing photoluminescence emitted by quantum dots conjugated to the secondary antibodies (FIG. 4 ). - From
FIG. 5 , it is clear that the ELISA-based assay (see Examples) did not detect Troponin I (in PBS buffer or healthy sera) at concentrations lower than about 0.1 nM, but gave highly reproducible signals at each Troponin I concentration. Using the chimeric nanoparticles and nickel nanohair system developed in the present invention, the sensitivity was surprisingly boosted to low 10−18 level (FIG. 6 ), which represents about 100.000-fold higher sensitivity than the highest level (0.25 μM) reported to date [Apple, F. S., Smith, S. W., Pearce, L. A., Ler, R. & Murakami, M. M. Clin. Chem. 54, 723-728 (2008)] and also 108˜107 greater sensitivity than current ELISA assays [Rosi, N. L. & Mirkin, C. A. Chem. Rev. 105, 1547-1562 (2005); Hirsch, L. R., Jackson, J. B., Lee, A., Halas, N. J. & West, J. Anal. Chem. 75, 2377-2381 (2003); Nam, J. M., Park, S. J. & Mirkin, C. A. J. Am. Chem. Soc. 124, 3820-3821 (2002); Niemeyer, C. M. & Ceyhan, B. DAngew. Chem., Int. Ed. 40, 3685-3688 (2001); Chien, R. J. et al. Proc. Natl. Acad. Sci. 100, 4984-4989 (2003); Wang, J., Polsky, R., Merkoci, A. & Turner, K. L. Angew. Chem., Int. Ed. 43, 2158-2161 (2004)]. As shown in the binding of the chimeric nanoparticles (i.e., in the step B ofFIG. 7 ), to prevent false signals of photoluminescence arising from non-specific binding of quantum dot secondary antibodies to the bare nickel surface, a sufficient amount of chimeric nanoparticles were added to the washed surface of the nickel nanohair as shown in the result of control ofFIG. 6 (FIG. 13 ). Furthermore, Troponin I in AMI patient sera was successfully detected using the same assay system and procedure, while the Troponin I-free PBS buffer and healthy sera gave only negligible signals (FIG. 6 ). - One of the distinct advantages of this assay system according to the present invention is that one nickel nanohair structure can be repeatedly used for multiple samples. Through washing and rinsing (i.e., in the step A of
FIG. 7 ), the used nickel nanohair was refreshed and reused for another sample assay. All of the three separate nickel nanohair structures were successfully used for the consecutive assay of eight different samples. Each consecutive assay showed reproducible and consistent signals for all the samples tested. - A polyvinylidene fluoride (PVDF) membrane with an average pore size of 450 nm was selected as a suitable nanostructure with a hydrophobic pore surface on which the chimeric nanoparticles were easily immobilized, and was used to construct another type of three-dimensional assay system. As seen in
FIG. 9 , antibodies attached on the chimeric nanoparticles could reproducibly detect Troponin I, at all concentrations, in both PBS buffer and healthy sera spiked with Troponin I. The atto-molar detection limit of Troponin I was also comparable to that of the nickel nanohair-based assay. Furthermore, the assay with antibodies directly immobilized on the PVDF surface showed significantly lower sensitivities than assays using the chimeric nanoparticles (FIG. 10 ). This is probably due to the orientation of the antibodies; those immobilized directly on the PVDF surface may be random and have lower accessibility to Troponin I. The orientation of antibodies immobilized on the chimeric nanoparticles seems crucial for the sensitivity of the assay. - The present inventors also tested the PVDF-based assay system in the clinical diagnosis of 26 AMI patients (Table 1) who were confirmed to have experienced an AMI, and the assay results were compared with the ELISA-based assay (a and b of
FIG. 11 ). In the ELISA-based assay (b ofFIG. 11 ), three (Nos. 4, 9, and 18) AMI patient sera were not positively detected; that is, the absorbance signals were below the clinical cutoff value (indicated by the horizontal dotted line), and the signals from nine (Nos. 1, 2, 3, 5, 8, 11, 16, 17, and 23) AMI patient sera were positive but very close to the clinical cutoff. Meanwhile, the chimeric nanoparticles and PVDF-based assay gave clear positive signals for all 26 AMI patient sera, therefore indicating 100% clinical specificity (FIG. 11 ). (The ELISA assay results were not surprising because the clinical specificity of the ELISA kit is reported by the supplier to be 87.5%.) Furthermore, antibodies directly immobilized on the PVDF surface failed to diagnose the 1,000-times diluted AMI patient sera, whereas the chimeric nanoparticles and PVDF-based assay could detect Troponin I in the diluted patient sera (FIG. 12 ), indicating that this three-dimensional assay can discriminate the onset of AMI even with an extremely small quantity of patient sera. - Using the HBV capsid-derived chimeric nanoparticles and three-dimensional nanostructures (nickel nanohair), we were able to develop a highly sensitive and specific assay system for the specific AMI marker, Troponin I. Although HBV capsid according to the present invention was used in this study as a model viral scaffold for the surface display of SPAB, other viruses or virus-like particles could also be used for the production of chimeric nanoparticles, displaying the surface SPAB. Owing to the controlled orientation of densely immobilized antibodies and the three-dimensional manner of protein capture, the assay sensitivity and clinical specificity were significantly enhanced as compared to the conventional ELISA assay.
- The nanohair wire structure according to the present invention, which is a method for chemically detecting that has a yield of a high efficiency due to the exclusion of agglomeration phenomenon among the nanowires, has a high applicability in the flied of Biotechnology (BT) as well as Nanotechnology (NT) by synthesizing the nanowire material having a biological functionality inside the nanotemplate. The present invention showed that the assay system according to the present invention using chimeric nanoparticles and three-dimensional nanostructure (nickel nanohair and PVDF membrane) has a very higher sensitivity and specificity as the use of detecting the disease diagnosis marker and has very high sensitivity and specificity to the protein marker, such as Troponin I or specific AMI marker.
- The present invention will now be described in more detail with reference to the following non-limited Examples. However, the following Examples are only for illustration to explain the present invention, but the range of the present invention will not be limited to the following Examples.
- —Synthesis of Nickel Nanowires—
- The anodized aluminum oxide (AAO) nanotemplate with uniform pore diameter (tens to hundreds nm) as shown in
FIG. 1( a) was synthesized. And then, Ag as a working electrode was deposited one side of AAO in a thickness of 250-350 nm using E-beam evaporator as shown inFIG. 1( b). Then, after adding AAO to the solution of nickel sulfate (NiSO46H2O, 0.5 M)+nickel chloride (NiCl2.6H2O, 0.1M)+boric acid (H3BO3, 0.1M) as shown inFIG. 1( c), Pt as a counter electrode was deposited to the nickel nanowires. Here, nickel sulfate is a main component of plating; nickel chloride was used for increasing an electrical conductivity; and boric acid was used as a buffer solution for pH homeostasis. - —Planarization of Nickel Nanowires—
- Then, as shown in
FIG. 1( c), the polishing was performed about 10 μm through a chemical mechanical planarization (CMP) process for identifying AAO nanotemplate with the height of nanowires that were overflow or underflow-gtown inside the AAO. - —Exposure of Nickel Nanowires on AAO—
- As a final step, a selective reactive ion etching (RIE) process of AAO nanotemplate was performed in order to expose the nickel nanowires. The process was performed by etching AAO for 10 min at an etching rate of 0.25 μm/min using BCl3 (100%) gas. And then, a cleaning process (DI water: ultrapure water, ethanol) was completed, finishing the process of the nickel nanohairs structure with a clean surface.
- Following assembly PCR using the primers as disclosed in the following Table 1, the present inventors prepared the two gene clones derived from the HBV core protein (HBVcAg) gene and code for the synthesis of N-NdeI-hexahistidine-HBVcAg(1-78)-G4SG4T-XhoI-C and N-BamH1-G4SG4-HBVcAg (81-149)-HindIII-C. To replace the P79A80 of the HBV cAg with the tandem repeat of SPAB (residues 209-271), the two different clones, N-XhoI-SPAa-EcoRI-C and N-EcoRI-SPAa-BamHI-C were prepared. Through the sequential ligation of the four above gene clones into plasmid pT7-7, we constructed the plasmid expression vector pT7-Chimera-HBV encoding the synthesis of N-His6-HBVcAg(1-78)-SPAB-SPAB-HBVcAg(81-149)-C. After the complete DNA sequencing of gel-purified plasmid expression vector, E. coli strain BL21 (DE3) [F−ompThsdSB(rB−mB−)] was transformed with pT7-Chimera-HBV, and ampicillin-resistant transformants were selected. The gene expression, purification and TEM image analysis of chimeric nanoparticles were performed by using the same method as disclosed in Ahn, J. Y. et al. Nucl. Acids Res. 33, 3751-3762 (2005).
- The information and the disclosure in more detail about the primer sequences and templates related to the fabrication of HBV capsid-derived chimeric nanoparticles are as follows:
-
TABLE 1 Gene Name Primer Seq. No. Sequence Hepatitis N-terminus Sense Seq. No. 1 cat atg cat cac cat cac cat cac gac B virus of HBV att gac ccg tat aaa gaa capsid capsid Anti Seq. No. 2 ccc act ccc tcc gcc acc gtc ttc caa (1-234 sense att act tcc cac cca Gene Anti Seq. No. 3 ctc gag agt acc gcc tcc ccc act ccc Sequence) sense tcc gcc acc C-terminus Anti Seq. No. 4 gga tcc gga tcc ggt ggc gga ggg of HBV sense tct ggg gga ggc ggt capsid Sense Seq. No. 5 ggc gga ggg tct ggg gga ggc ggt (241-447 tcc agg gga tta gta gtc agc tat Gene Anti Seq. No. 6 aag ctt tta aac aac agt agt ttc cgg Sequence) sense aag B domain of Sense Seq. No. 7 ctc gag gca ccg aaa gct gat aac Staphylococcal Anti Seq. No. 8 gaa ttc gtc agc ttt tgg tgc ttg protein A sense Sense Seq. No. 9 gaa ttc gca ccg aaa gct gat aac Anti Seq. No. 10 gga tcc gtc agc ttt tgg tgc ttg sense - Table 1 shows primer sequences, in which bold types represent restriction enzymes sequences; underlined parts represent linker sequences; and italic types represent 6 histidine sequences.
- HBV capsid-derived chimeric nanoparticles can be largely divided into 1-78 amino acid sequence regions of capsid protein, the region including continuously two Staphylococcal protein A, and 81-149 amino acid sequences regions of capsid protein (1-78 sequences of capsid protein is NCBI Nucleotide accession number: AF286594 sequences: 1901-2134 (Sequence No. 12) and amino acid sequence (Sequence No. 13); 81-149 sequences of capsid protein is 2141-2347 sequences (Sequence No. 14) of AF286594; and the amino acid sequence is Sequence No. 15, and Protein A sequence is NCBI nucleotide accession No. M18264, nucleotide sequence 625-813 (Sequence No. 11); and the amino acid is Sequence No. 16).
- The first region was subjected to extension PCR using the
primer sequence region 1 including 6 histidines using the gene sequence of HBV capsid protein (1901-2452 sequences of NCBI Nucleotide accession number: AF286594 sequences) as a template, and theprimer sequences primer sequences primer sequences - Using the second region, two protein A and B domains forming 5′-XhoI-SPAB-EcoRI-3′ and 5′-EcoRI-SPAB-BamHI-3′ using the
primer sequences - The third region was subjected to extension PCR using the
primer sequence 6, and theprimer sequences primer sequences primer sequences - Nickel Nanohair-Based System:
- The nickel nanohair structure prepared by the above Example 1 was placed in the Costar 96-well plate (Cat. No. 3599, Corning, N.Y., USA). Before immobilizing the chimeric nanoparticles, the nickel nanohair in each well was washed four times for 15 min using 0.3 M sulphuric acid and then six times for 10 min using distilled water, then completely dried. Next, the background photoluminescence from the nickel nanohair structure was measured using a microplate reader (GENios, Tecan, Austria) with excitation and emission at 420 and 650 nm, respectively. PBS buffer (50 μl) containing the 38-nM chimeric nanoparticles prepared from Example 2 was added to the nickel nanohair structure, followed by slow agitation for 30 min, after which it was washed with 50 mM Tris buffer (pH 7.4). Rabbit anti-troponin polyclonal antibody (5 μg/ml, Cat. No. ab470003, Abcam, Cambridge, UK) in 200 μl PBS buffer was added to the chimeric nanoparticles that were already immobilized on the nickel nanohair, by slowly stirring the nickel nanohair in the antibody-containing PBS buffer for 2 h.
- PVDF-Based System:
- PVDF membrane (Immobilion-FL, IPFL 10100, Millipore, Mass., U.S.A.) in a Costar 96-well plate was pre-wetted with methanol for 1 min and washed with a PBS buffer (137 mM, NaCl; 2.7 mM, KCl; 10 mM, Na2HPO4; 2 mM, KH2PO4; pH, 7.4) for 5-10 min. Before the PVDF membrane was completely dried, 10 a of PBS buffer containing the chimeric nanoparticles purified in Example 2 was dropped onto a designated spot on the membrane. The membrane was then slowly stirred for 1 h in the blocking solution (1% skimmed milk) and washed twice with the PBS buffer for 30 min. Goat anti-Troponin I polyclonal antibodies (20 μg/ml in PBS buffer; Cat. No. 70-XG82, Fitzgerald, Mass., USA) was added to the chimeric protein nanoparticles that were already immobilized onto the PVDF membrane, by slowly stirring the membrane in the antibody-containing 200 μl PBS buffer for 2 h.
- To the three-dimensional diagnostic system consisting of anti-Troponin I antibodies, HBV capsid-derived chimeric nanoparticles prepared in Example 2, and nickel nanohair structure (or PVDF membrane) prepared in Example 1, 200 μl Troponin (human cardiac Troponin I-T-C complex, Cat. No. 8T62, HyTest, Finland) that had been properly diluted in PBS buffer or human serum (AMI patient or healthy serum) was added, then stirred for 20 s, and incubated at room temperature for 1 h. After washing for 5 min using PBS buffer, 200 μl mouse anti-Troponin I monoclonal antibodies (3.2 μg/ml, Cat. No. 4T21, HyTest, Finland) in PBS buffer was added, stirred for 20 s, incubated at room temperature for 1 h, and then washed for 5 min using PBS buffer. 200 μl Q-dot (CdSe)-secondary Ab conjugate [1 nM, Qdot 655-Goat F(ab′)2 anti-mouse IgG conjugate, Cat. No. Q11021MP, Invitrogen, Carlsbad, Calif., USA] was added, stirred for 20 s, incubated at room temperature for 1 h, and finally washed for 10 min with PBS buffer. Photoluminescence was then measured using a microplate reader (GENios, Tecan, Austria) with excitation and emission at 420 and 650 nm, respectively.
- All the ELISA assay experiments in the present invention were conducted using the commercial ELISA Troponin assay kit (Troponin I EIA, Cat. No 25-TR1HU-E01, 96 wells, ALPCO Diagnostics, NH, USA) that was developed for in vitro diagnostic use. In short, it is as follows: 1) 100 μl of human serum (AMI patient or healthy serum) or Troponin (human cardiac Troponin I-T-C complex, Cat. No. 8T62, HyTest, Finland) in PBS buffer was added to antibody-coated 96-wells microplate provided by a provider; 2) 100 μl of enzyme conjugated reagent (containing HRP enzyme-conjugated anti-Troponin I antibodies) was added to each well, stirred sufficiently for 30 s, incubated at room temperature for 90 min, and then washed five times with distilled water; 3) after the well was allowed to strike hard it on an absorption paper in order to remove the entire remained water drop, 100 μl of “TMB reagent (containing the substrate to HRP enzyme)” was added to each well, mixed for 5 s, and then incubated at room temperature for 20 min; 4) 100 μl of “Stop solution” was added to each well in order to stop the enzyme reaction, then mixed for 30 s, and then the absorbance was measured by using the microplate reader (GENios, Tecan, Austria) at 420 nm.
- Troponin I EIA provides a reliable assay for the quantitative measurement of human cardiac-specific Troponin I with a clinical specificity of 87.5 The procedure disclosed in Troponin I EIA protocol was strictly followed for the Troponin I assay, and the assay procedure is as follows. The entire list of AMI patients and healthy sera are disclosed in Table 2.
-
TABLE 2 No. Age Sex Hospital AMI Patient Serum 1 74 M KangNam Sacred Heart Hospital 2 75 F 3 58 M 4 68 M 5 63 M 6 80 M 7 59 M 8 68 M 9 74 M 10 77 F 11 86 F 12 85 F 13 52 F 14 43 M 15 68 M 16 59 F 17 84 F 18 58 M 19 37 M 20 42 M Korea University Medical Center 21* 3 F 22 91 M 23 72 F 24 79 F 25 89 F 26 57 M Healthy serum 1 34 M Korea University Medical Center 2 24 M 3 28 M 4 25 F 5 45 M 6 24 M 7 27 M 8 24 F 9 31 F 10 25 M 11 30 F 12 24 M 13 26 F 14 48 M 15 26 F 16 29 M [*Person experienced with a myocardium damage due to a heart septal defect operation using an extracorporeal circulation]
Claims (14)
1. A nanohair structure comprising:
(a) nanotemplate comprising a plurality of pores; and
(b) a plurality of nanowires grown through the pores of the nanotemplate, wherein one portion of the nanowires is embedded inside the nanotemplate, while the other portion of the nanowires is exposed vertically on top of the surface of the nanotemplate.
2. The nanohair structure according to claim 1 , wherein the nanowire is derived from one of transition metal species which is selected from the group consisting of Ni, Fe, Co, Ni, Cu, Ag, Au, Pd and Pt, alloy thereof or oxide, nitride or carbide thereof.
3. The nanohair structure according to claim 1 , wherein the nanotemplate is anodized aluminum oxide (AAO) or poly-carbonate membrane.
4. The nanohair structure according to claim 1 , wherein the nanowire is derived from electrically conductive polymer.
5. A method of the nanohair structure comprising, a) preparing a nanotemplate with a plurality of pores; b) generating electrode layer on one side of the nanotemplate; c) putting the nanotemplate into the solution containing the metal ion and growing the metal nanowire through pores of the nanotemplate by electrodeposition employing it as a cathode; d) planarizing the metal nanowire through a process of chemical mechanical planarization (CMP); and e) selectively reactive ion etching (RIE) of the nanotemplate.
6. The method of the nanohair structure according to claim 5 , wherein the thickness of the layer of step b) is 250-350 nm.
7. The method of the nanohair structure according to claim 5 , wherein the metal ion is selected from the group consisting of Ni, Fe, Co, Ni, Cu, Ag, Au, Pd and Pt ion.
8. The method of the nanohair structure according to claim 5 , wherein the method further comprises the step of modifying the exposed part of the nanohair into oxide, nitride or carbide of metal or alloy thereof through post-treatment process of oxidation, nitrification or carburization of the exposed part after preparing the nanohair structure.
9. The method of the nanohair structure according to claim 5 , wherein the nanotemplate is anodized aluminum oxide or poly-carbonate membrane.
10. A three-dimensional nanostructure-based nanosensor fabricated by adding chimeric nanoparticles to the nanohair structure according to claim 1 and immobilizing the chimeric nanoparticles to the nanohair structure.
11. The three-dimensional nanostructure-based nanosensor according to claim 10 , wherein the chimeric nanoparticle is a HBV-derived chimeric protein.
12. The three-dimensional nanostructure-based nanosensor of claim 10 , wherein the nanosensor further comprises an antibody which recognizes a specific disease marker.
13. The three-dimensional nanostructure-based nanosensor according to claim 12 , wherein the specific disease marker is Troponin I.
14. A nanowire-based electrode comprising nanohair structure according to claim 1 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/189,552 US20140209475A1 (en) | 2009-03-06 | 2014-02-25 | Nanohair structure and an application therefor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0019355 | 2009-03-06 | ||
KR20090019355 | 2009-03-06 | ||
PCT/KR2010/001389 WO2010101437A2 (en) | 2009-03-06 | 2010-03-05 | Nanohair structure and an application therefor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/001389 Continuation WO2010101437A2 (en) | 2009-03-06 | 2010-03-05 | Nanohair structure and an application therefor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/189,552 Division US20140209475A1 (en) | 2009-03-06 | 2014-02-25 | Nanohair structure and an application therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120325669A1 true US20120325669A1 (en) | 2012-12-27 |
Family
ID=42710076
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/225,088 Active US8586370B2 (en) | 2009-03-06 | 2011-09-02 | Chimeric protein, method for manufacturing the same, nano-sensor in which the chimeric protein is fixed, and application thereof |
US13/225,167 Abandoned US20120325669A1 (en) | 2009-03-06 | 2011-09-02 | Nanohair structure and an application therefor |
US14/189,552 Abandoned US20140209475A1 (en) | 2009-03-06 | 2014-02-25 | Nanohair structure and an application therefor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/225,088 Active US8586370B2 (en) | 2009-03-06 | 2011-09-02 | Chimeric protein, method for manufacturing the same, nano-sensor in which the chimeric protein is fixed, and application thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/189,552 Abandoned US20140209475A1 (en) | 2009-03-06 | 2014-02-25 | Nanohair structure and an application therefor |
Country Status (3)
Country | Link |
---|---|
US (3) | US8586370B2 (en) |
KR (3) | KR101163535B1 (en) |
WO (2) | WO2010101355A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140302303A1 (en) * | 2011-10-26 | 2014-10-09 | Brandeis University | Aligned arrays of nanorods, and methods of making and using them |
US20140338961A1 (en) * | 2011-11-28 | 2014-11-20 | Snu R&Db Foundation | Member for flexible element and manufacturing method thereof |
US20150200058A1 (en) * | 2009-08-26 | 2015-07-16 | University Of Maryland | Nanodevice arrays for electrical energy storage, capture and management and method for their formation |
US20180321177A1 (en) * | 2017-05-08 | 2018-11-08 | Tsinghua University | Biosensor electrode and biosensor using the same |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106573960B (en) * | 2014-06-02 | 2021-07-02 | Isa制药有限公司 | Synthetic Long Peptides (SLP) for therapeutic vaccination against hepatitis B virus infection |
US9994715B2 (en) * | 2016-02-16 | 2018-06-12 | Sila Nanotechnologies Inc. | Formation and modifications of ceramic nanowires and their use in functional materials |
US10768139B2 (en) * | 2016-09-08 | 2020-09-08 | The Francis Crick Institute Limited | Electrochemical probe |
KR102211590B1 (en) | 2019-10-24 | 2021-02-02 | 한국화학연구원 | Preparation method of nanowire array for diagnosis middle east respiratory syndrome virus |
KR102309495B1 (en) | 2021-01-11 | 2021-10-05 | 한국화학연구원 | Nanowire-based immunofluorescence kits for the detection of severe acute respiratory syndrome coronavirus 2 antibodies and uses thereof |
KR20230102652A (en) | 2021-12-30 | 2023-07-07 | 한국화학연구원 | Preparation method of zinc oxide nanowire array for the detection on tuberculosis antigen or antibody |
GB202204803D0 (en) * | 2022-04-01 | 2022-05-18 | Univ Manchester | Virus-like particles |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6504292B1 (en) * | 1999-07-15 | 2003-01-07 | Agere Systems Inc. | Field emitting device comprising metallized nanostructures and method for making the same |
US20060275955A1 (en) * | 2005-06-01 | 2006-12-07 | General Electric Company | Patterned nanorod arrays and methods of making same |
US20060292870A1 (en) * | 2003-10-13 | 2006-12-28 | Centre National De La Recherche | A method of synthesizing nanoscale filamentary structures and electronic components comprising such structures |
US20080241755A1 (en) * | 2007-02-01 | 2008-10-02 | Franklin Aaron D | Contact metallization of carbon nanotubes |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030198956A1 (en) | 2002-02-21 | 2003-10-23 | Lee Makowski | Staged assembly of nanostructures |
US20030013079A1 (en) * | 2001-06-21 | 2003-01-16 | Petropoulos Christos J. | Production of infectious hepadnavirus particles containing foamy retrovirus envelope proteins and methods of using the same |
KR20030084279A (en) * | 2002-04-26 | 2003-11-01 | 이진규 | A method for preparing large-area materials with well-defined nanostructure using nanoporous alumina or nano-textured aluminum |
US7632234B2 (en) | 2003-08-29 | 2009-12-15 | Medtronic, Inc. | Implantable biosensor devices for monitoring cardiac marker molecules |
JP4109205B2 (en) * | 2004-01-07 | 2008-07-02 | 富士フイルム株式会社 | Analyte detection method |
JP5313664B2 (en) * | 2006-04-19 | 2013-10-09 | 独立行政法人科学技術振興機構 | Manufacturing method of substrates with minute metal blocks aligned on the surface |
US8936794B2 (en) * | 2006-08-25 | 2015-01-20 | The Regents Of The University Of Michigan | Conducting polymer nanotube actuators for precisely controlled release of medicine and bioactive molecules |
KR100885434B1 (en) * | 2007-10-12 | 2009-02-24 | 연세대학교 산학협력단 | Resistive ramdom access memory device and method of the same |
US20100006451A1 (en) * | 2008-07-11 | 2010-01-14 | Neil Gordon | Biosensing device and method for detecting target biomolecules in a solution |
-
2010
- 2010-02-02 WO PCT/KR2010/000640 patent/WO2010101355A2/en active Application Filing
- 2010-03-05 KR KR1020100019686A patent/KR101163535B1/en active IP Right Grant
- 2010-03-05 WO PCT/KR2010/001389 patent/WO2010101437A2/en active Application Filing
-
2011
- 2011-09-02 US US13/225,088 patent/US8586370B2/en active Active
- 2011-09-02 US US13/225,167 patent/US20120325669A1/en not_active Abandoned
- 2011-11-15 KR KR1020110119198A patent/KR101267260B1/en active IP Right Grant
-
2012
- 2012-04-10 KR KR1020120037540A patent/KR101309560B1/en active IP Right Grant
-
2014
- 2014-02-25 US US14/189,552 patent/US20140209475A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6504292B1 (en) * | 1999-07-15 | 2003-01-07 | Agere Systems Inc. | Field emitting device comprising metallized nanostructures and method for making the same |
US20060292870A1 (en) * | 2003-10-13 | 2006-12-28 | Centre National De La Recherche | A method of synthesizing nanoscale filamentary structures and electronic components comprising such structures |
US20060275955A1 (en) * | 2005-06-01 | 2006-12-07 | General Electric Company | Patterned nanorod arrays and methods of making same |
US20080241755A1 (en) * | 2007-02-01 | 2008-10-02 | Franklin Aaron D | Contact metallization of carbon nanotubes |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150200058A1 (en) * | 2009-08-26 | 2015-07-16 | University Of Maryland | Nanodevice arrays for electrical energy storage, capture and management and method for their formation |
US10032569B2 (en) * | 2009-08-26 | 2018-07-24 | University Of Maryland, College Park | Nanodevice arrays for electrical energy storage, capture and management and method for their formation |
US20140302303A1 (en) * | 2011-10-26 | 2014-10-09 | Brandeis University | Aligned arrays of nanorods, and methods of making and using them |
US11421046B2 (en) * | 2011-10-26 | 2022-08-23 | Brandeis University | Aligned arrays of nanorods, and methods of making and using them |
US20140338961A1 (en) * | 2011-11-28 | 2014-11-20 | Snu R&Db Foundation | Member for flexible element and manufacturing method thereof |
US9510445B2 (en) * | 2011-11-28 | 2016-11-29 | Snu R&Db Foundation | Member for flexible element and manufacturing method thereof |
US20180321177A1 (en) * | 2017-05-08 | 2018-11-08 | Tsinghua University | Biosensor electrode and biosensor using the same |
US10852267B2 (en) * | 2017-05-08 | 2020-12-01 | Tsinghua University | Biosensor electrode and biosensor using the same |
Also Published As
Publication number | Publication date |
---|---|
WO2010101437A3 (en) | 2011-01-06 |
US8586370B2 (en) | 2013-11-19 |
KR101163535B1 (en) | 2012-07-06 |
US20140209475A1 (en) | 2014-07-31 |
KR20100100686A (en) | 2010-09-15 |
KR20120054574A (en) | 2012-05-30 |
KR101309560B1 (en) | 2013-09-23 |
KR20110134356A (en) | 2011-12-14 |
WO2010101355A3 (en) | 2011-04-07 |
US20120149120A1 (en) | 2012-06-14 |
WO2010101437A2 (en) | 2010-09-10 |
WO2010101437A9 (en) | 2010-11-25 |
KR101267260B1 (en) | 2013-05-28 |
WO2010101355A2 (en) | 2010-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20140209475A1 (en) | Nanohair structure and an application therefor | |
US9993794B2 (en) | Single molecule loading methods and compositions | |
JP2005513999A (en) | Oligonucleotide identifier | |
KR102016668B1 (en) | DNA aptamer binding specifically to chikungunya virus envelope protein 2(CHIKV E2) and uses thereof | |
KR20090131588A (en) | Real-time detection devices by continuous monitoring | |
Liu et al. | Sandwich pair nanobodies, a potential tool for electrochemical immunosensing serum prostate-specific antigen with preferable specificity | |
Malima et al. | Highly sensitive microscale in vivo sensor enabled by electrophoretic assembly of nanoparticles for multiple biomarker detection | |
KR20110090347A (en) | A chimeric protein, a preparation method thereof, a nanosenser fixed with the same and an application thereof | |
JP5883386B2 (en) | Protein or peptide printing method, protein array or peptide array production method, and functional protein or functional peptide identification method | |
CN104535769A (en) | Method for preparing bio-macromolecular monomolecular chip by virtue of high-density nano-hollow | |
KR101970963B1 (en) | DNA aptamer binding specifically to yellow fever virus envelope protein domain III (YFV EDIII) and uses thereof | |
Chen et al. | Signal-off/on electrogenerated chemiluminescence deoxyribosensors for assay of early lung cancer biomarker (NAP2) based on target-caused DNA charge transfer | |
US20050277205A1 (en) | Multicomponent magnetic nanorods for biomolecular separations | |
CA2629931A1 (en) | Method | |
KR100877187B1 (en) | Protein chip and detection method of the same comprising protein nanoparticles linked with epitope recognizing disease marker for diagnosis | |
Ravalli et al. | Electrochemical‐based biosensor technologies in disease detection and diagnostics | |
KR101551925B1 (en) | Target-specific probe comprsing t7 bacteriophage and detecting for biomarker using the same | |
US7919332B2 (en) | Biological molecule-immobilized chip and its use | |
Kaur et al. | Biosensors for Disease Diagnosis | |
Erkmen et al. | Nanobiosensors: Construction and Diagnosis of Disease | |
Mathew | Nanoscale Electrodes for Bionanosensing | |
KR101395398B1 (en) | Virus-microbead complex and use thereof | |
JP2022025992A (en) | Micro structure and molecule detecting method | |
Zaitouna | Surface-based whole protein detection via electrochemical peptide-based sensors | |
JP2005289822A (en) | Method for anchoring biomolecule onto magnetic support by using membrane-penetrating peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, YOUNG KEUN;LEE, JEE WON;PARK, JIN SEUNG;AND OTHERS;SIGNING DATES FROM 20111111 TO 20111115;REEL/FRAME:027264/0856 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |